Q1 2026 marked significant growth in venture financing and strategic investments across China’s biotech scene, with disclosed capital totaling $1.75B spanning 50+ transactions. Key highlights include:

• Record Venture Rounds: JeYou Pharmaceutical raised $278M (Series A) for multi-modality platforms, and Corxel Pharmaceuticals secured $287M (Series D1) for small molecule innovations.
• Sector Trends: Nucleic acid companies like Hygieia (acquired for $167M) and NanoRibo ($88M) led M&A activity, showing RNA technologies’ emergence as prime acquisition targets.
• Strategic Global Investments: Syneron Bio captured $150M (Series B) backed by AstraZeneca, Pfizer, and Abu Dhabi’s ADIA, spotlighting sovereign and multinational confidence in AI-driven peptide platforms.